Summary Slide.png (66.34 kB)

Golimumab as First, Second or at Least Third Biologic Agent in Patients With Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis -Post Hoc Analysis of a Non-Interventional Study in Germany

figure

posted on 2020-04-09, 15:59 authored by Klaus Krüger, Gerd Rüdiger Burmester, Siegfried Wassenberg, Matthias. H. Thomas

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s40744-020-00204-9

Usage metrics

Read the peer-reviewed publication

Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany

Rheumatology and Therapy

Keywords

Ankylosing spondylitis First-Golimumab Non-interventional study Psoriatic arthritis Real-word evidence Rheumatoid arthritis Second-Third line

Licence

CC BY-NC 4.0